Skip to main content

Fiscal Wizard · Single-issue tearsheet

REGN / Oct 1, 2026 Run #19173
Paper trade

REGN

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Composite verdict

A 78.5 / 100
Bullish setup · Mean Reversion 11 drivers · 3 gates blocking
  • MA Rejection
  • Stochastic Cross
  • Bollinger Reentry
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 4th of 21 in Biotechnology

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 16 signals0% Bear
Momentum Bullish 65Mean-reversion Bullish 84
  • Pullback buyOversold in an uptrend — a pullback buy: mean-reversion aligned with the primary trend, the high-value case for an oversold signal. (medium confidence)
Where value comes fromMargin of safety -50%
Asset value $309.05Earnings power value $349.72Price $734.81

Priced above its no-growth earnings power value ($349.72/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

57.0 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Greenblatt EY 81
Margin of Safety 0
OCF to Net Income 79
Total Shareholder Yield 0
EV/FCF 79
Inventory Turnover 0

Technicals Bullish

99.9 / 100

Bullish setup leads (MA Rejection, Stochastic Cross, Bollinger Reentry); bears gated by guards. · 44 signals shown.

Strongest
Weakest
Stochastic Cross 89
MA Rejection 89
Commodity Channel Index 87

Risk Gates

3 blocking 3 caution

3 guards active, 28 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for REGN.